PRESS RELEASE: Seven High-Profile Patient Engagement Leaders to Advise Nonprofit on its Patient-Focused Research Agenda

Alexandria, VA – May 6, 2020 – The Innovation and Value Initiative (IVI), a research-based non-profit improving the science and practice of value assessment, today announced the appointment of seven members to its Patient Advisory Council, and advisory body designed to ensure the patient always remains at the forefront of value assessment. The Council, which [...]

2020-05-06T12:17:47-06:00May 6th, 2020|IVI News, Press|

PRESS RELEASE: IVI Convenes First-of-its-Kind Multi-Stakeholder Summit to Accelerate Aligning Value Assessment Methods with Real-World Decision Needs

Participants Define Consensus Expectations and Prioritize Research Agenda to Improve Value Assessment Methods Alexandria, VA – March 17, 2020 – The Innovation and Value Initiative (IVI), a research-based non-profit improving the science and practice of value assessment, recently hosted a first-of-its-kind multi-stakeholder summit to examine current gaps and emerging approaches in value assessment. The program [...]

2020-03-20T11:51:10-06:00March 17th, 2020|IVI News, Press|

PRESS RELEASE: Dr. Patricia Deverka Appointed as IVI’s First Chief Science Officer

IVI is thrilled to announce Pat Deverka, MD has joined our organization as our first Chief Science Officer. Dr. Deverka. Dr. Deverka brings to IVI more than three decades of experience in health economic research, public policy, patient engagement and program measurement across several academic, corporate and non-profit institutions. Read the full press release [...]

2020-02-03T12:45:09-06:00February 4th, 2020|IVI News, Press|

PRESS RELEASE: IVI’s Updated RA Model Examines New Treatment Options, Treatment Effects and Cost Estimates

IVI has just released the latest update to the organization's Rheumatoid Arthritis (RA) Value Assessment Model. The updated model now incorporates additional treatment options (triple therapy, Janus Kinase (JAK) inhibitors, sarilumab, and biosimilars), updated treatment effect estimates based on additional randomized controlled trial (RCT) evidence, and updated cost estimates. The model is also designed to [...]

2020-01-07T00:30:08-06:00January 7th, 2020|IVI News, Press|

PRESS RELEASE: IVI Research Brief Discusses Limitations of ICER’s Analysis for JAK Inhibitors

As part of its Value Blueprints series, IVI’s latest research brief grapples with a question prompted by ICER’s recent assessment of RA therapies: Do conventional value assessments address the questions most relevant to real-world decisions about treatment pathways for chronic diseases? In the brief, the authors discuss how the failure of ICER’s analysis to evaluate [...]

2019-12-10T13:20:31-06:00December 10th, 2019|IVI News, Press|

PRESS RELEASE: IVI Receives Eugene Washington PCORI Engagement Award

IVI has been selected by the Patient-Centered Outcomes Research Institute (PCORI) for a Eugene Washington PCORI Engagement Award. The $50,000 award will be used to convene a multi-stakeholder forum in February 2020 to review established and emerging approaches for improving value assessment and then identify and prioritize potential areas for research investment and collaborative solutions. [...]

2019-10-08T10:49:54-06:00October 8th, 2019|IVI News, Press|

PRESS RELEASE: How Structural Uncertainty Impacts Value Estimates

In a new Value Blueprints research brief, IVI explores the concept of “structural uncertainty,” an important source of uncertainty that is not generally measured or addressed in cost-effectiveness models. In this research brief, we use the IVI-RA model to demonstrate how different structural assumptions lead to varying cost-effectiveness estimates. As our findings make clear, it [...]

2020-03-19T15:43:27-06:00September 4th, 2019|IVI News, Press, Publications|

PRESS RELEASE: IVI Illustrates “Insurance Value” Using IVI-RA Model in Latest Research Brief

In a new Value Blueprints research brief, IVI explores the novel concept of “Insurance Value.” New medical technologies not only benefit patients, but also healthy people at risk of future illness. The insurance value arising from the decreased physical risk from illness is a potentially important dimension to consider in value assessment, especially when decisions [...]

2020-03-19T15:43:47-06:00July 25th, 2019|IVI News, Press, Publications|

PRESS RELEASE: IVI Releases Public Comments on Non-Small Cell Lung Cancer Value Tool

Thank you for your comments! IVI has released all public feedback received during the open comment period for the IVI-NSCLC model - our open-source platform to assess therapy sequences for EGFR+ non-small cell lung cancer. In the spirit of IVI's mission of collaboration, commitment to transparency, and dedication to iterative improvement, we look forward to [...]

2019-07-18T13:08:44-06:00July 18th, 2019|IVI News, Press|